Tag - SONN

Developments

USPO issues NOA to Sonnet for second IL-18 protein patent

Sonnet BioTherapeutics (NASDAQ:SONN) announced that the United States Patent and Trademark Office (USPTO) has granted a notice of allowance (NOA) for a second patent in the IL-18 variant protein field. According to...

March 19, 2025

Markets

BTIG starts Sonnet BioTherapeutics at buy; PT $5

BTIG launched coverage of Sonnet BioTherapeutics (NASDAQ:SONN) with a “buy” rating and price target of $5. The stock closed at 56 cents on Sept. 14. Sonnet is an early-stage biotechnology company working to develop...

September 15, 2021

Tag - SONN

USPO issues NOA to Sonnet for second IL-18 protein patent

BTIG starts Sonnet BioTherapeutics at buy; PT $5

Subscribe